Pharmaceutical and Biotechnology Royalty Rates Agreements Analysis Report 2025 with Directory of 700+ Deals Signed Since 2015 - Upfront, Milestone, Royalties, Company A-Z, Deal Type & Therapy Area - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025" report has been added to ResearchAndMarkets.com's offering.

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 700+ partnering deals disclosing royalty rates from 2010 to 2025. The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

Report Scope

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals, available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

1.1. What are royalties?

1.2. History of royalty rates

1.3. Royalties in pharmaceuticals and biotechnology

1.4. Royalties versus revenue share

1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

2.1. Trends in royalty rates 2010 - 2025

2.2. How do revenue shares figure?

2.3. A review of recent literature

2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

3.1. Partnering agreement structure

3.2. Structure of a typical royalty clause

3.3. Example royalty clauses

Chapter 4 - Companies actively disclosing royalty rates

4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight

Deal Directory

• Deal directory - Royalty rates in deals - by company A-Z
• Deal directory - Royalty rates in deals - by therapy area
• Deal directory - Royalty rates in deals - by stage of development at signing
• Deal directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document

For more information about this report visit https://www.researchandmarkets.com/r/4j3mow

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.